Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

This publication has 28 references indexed in Scilit:

• Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
  American Heart Journal, 2003
• Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality
  American Heart Journal, 2003
• Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
  Journal of the American College of Cardiology, 2003
• No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran
  Clinical Pharmacokinetics, 2003
• No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers
  Clinical Pharmacokinetics, 2003
• Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions
  Clinical Pharmacokinetics, 2003
• Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
  Clinical Pharmacokinetics, 2003
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
  Stroke, 1991
• Interobserver agreement for the assessment of handicap in stroke patients.
  Stroke, 1988
• The Barthel ADL Index: A reliability study
  International Disability Studies, 1988